Hepatitis C Management in Special Populations
Summary
- The AASLD/IDSA (Management Guidelines)[AASLD-IDSA HCV] and EASL (Management Guidelines)[EASL HCV] guidance panels provide recommendations for the use of DAA regimens in the treatment of HCV infection in patients with decompensated cirrhosis: Table 12
- There are now several regimens with DAAs that are recommended
- Choice of regimen depends on genotype, treatment experience, and ribavirin eligibility
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content